Top of this page
Skip navigation, go straight to the content

An attractive pipeline

For a medium-sized biopharma company, UCB has an attractive pipeline of large and small molecules.
Some of these are intended to strengthen the company's positions in disease areas such as epilepsy or rheumatoid arthritis. Others could take the company into new areas of severe disease such as systemic lupus erythematosus and osteoporosis.

UCB believes that this pipeline possesses immense potential for future growth as well as improving the quality of life for patients.

Here is an overview of the major projects currently being developed by UCB:

Small molecule drug / NCE

Small molecule drug / NCE

Antibody-based drug / NBE

Antibody-based drug / NBE



CNS Indications Phase 1 Phase 2 Phase 3 Filed
Neupro®advanced Parkinson's disease (U.S.)phase 4
Neupro®
restless legs syndrome (U.S.)phase 4
Vimpat®
epilepsy - monotherapy (U.S.)phase 3 half
brivaracetamepilepsy - adjunctive therapy
phase 2
Vimpat®epilepsy - monotherapy (EU)
phase 2
Vimpat®epilepsy - paed. adjunctive therapy1
phase 2 half
Vimpat®epilepsy - adjunctive therapy PGTCS2
phase 2 half
UCB0942epilepsy refactory
phase 1 half
Immunology Indications Phase 1 Phase 2 Phase 3 Filed
Cimzia®rheumatoid arthritis (Japan) phase 3 half
Cimzia®psoriatic arthritisphase 3 half
Cimzia®ankylosing spondylitisphase 3 half
epratuzumabsystemic lupus erythematosusphase 3 half
Cimzia®juvenile rheumatoid arthritis
phase 2
CDP7851fracture healingphase 2 half
CDP7851post-menopausal osteoporosisphase 2 half
olokizumabrheumatoid arthritis
phase 1
CDP7657systemic lupus erythematosusphase 1 half
1. Paediatric 2-17 years
2. Primary generalised tonic clonic seizures